What is it about?
This article explores how common pain relievers (NSAIDs) interact with the immune system during COVID-19 and other infections, aiming to guide future treatment. While reducing inflammation, they may affect the body's defense against viruses and show promise in enhancing certain therapies.
Featured Image
Photo by CDC on Unsplash
Why is it important?
The paper provides insights into the unique antiviral and immunomodulatory properties of NSAIDs, highlighting their potential as alternative or adjunctive therapeutic strategies in viral and bacterial infection management. It also emphasizes the need for further research, including randomized controlled trials, to deepen the understanding of the molecular interactions between NSAIDs and SARS-CoV-2 and to evaluate the long-term ramifications of NSAID utilization among COVID-19 patients.
Perspectives
I hope this article conveys the message that my co-authors and I intended—that NSAIDs work in various ways to fight viral infections like COVID-19. We've spent three years detecting new treatment strategies for future pandemics, aiming to approach them differently than how we tackled COVID-19.
Dr. Said Moshawih
Universiti Brunei Darussalam
Read the Original
This page is a summary of: Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies, Heliyon, February 2024, Elsevier,
DOI: 10.1016/j.heliyon.2024.e25734.
You can read the full text:
Contributors
The following have contributed to this page
